This is a working overview of triple agonist, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-07-10 and is reviewed periodically as new material appears.
Acting as a triple agonist, the molecule binds the GLP-1, GIP, and glucagon receptors. GLP-1 activity slows gastric emptying and dampens appetite, while GIP signaling contributes to insulin sensitivity and fat metabolism. Glucagon receptor engagement raises energy expenditure and encourages fat breakdown, although it can also elevate blood glucose. Combining three pathways is intended to yield larger weight reduction than single or dual agonists, and researchers continue to examine how the balance among them shapes tolerability.
Clinical studies have reported notable reductions in body weight among participants. Early trials measured safety and explored several dose levels, and later studies tracked body-weight change over months of treatment. Investigators also monitor effects on glycemic markers, liver fat, and blood lipids. Because the compound is still in development, questions about long-term safety, cardiovascular outcomes, and durability after treatment ends remain open.
The three-receptor design places retatrutide in a distinct category relative to older incretin-based therapies. Single agonists target one receptor, and dual agonists target two. Adding a third target broadens the pharmacological footprint and introduces new trade-offs among efficacy, tolerability, and glucose control. How these trade-offs resolve in large trials is a central focus of current research.
Mechanistic proposals link each receptor to a different physiological role. Activation of the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors is associated with reduced appetite, slower gastric emptying, and glucose-dependent insulin release. Glucagon receptor signaling, by contrast, is associated with increased energy expenditure and altered lipid handling, though it can also raise blood glucose. The design intent is to balance these contributions so that weight reduction is enhanced without unacceptable glycemic trade-offs. How well that balance holds across individuals is not fully resolved.
Published information places retatrutide in clinical development rather than on the market as an approved therapy. Early-stage and mid-stage trials have examined tolerability and changes in body weight, and larger studies continue to report results over time. Open questions include the durability of effects after treatment stops, the composition of weight lost, and cardiovascular outcomes over long periods. Statements about definitive benefit should therefore be treated as provisional. Regulatory status varies by jurisdiction and changes as applications are reviewed.
Retatrutide is an investigational synthetic peptide designed to activate three distinct receptor systems within a single molecule. Its pharmacological profile combines activity at the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This arrangement places it within a broader class of agents often described as multi-agonists, which contrast with compounds that engage one or two targets. Research interest centers on whether simultaneous signaling produces effects that single-receptor agonists cannot achieve alone. A single molecular entity also simplifies manufacturing and delivery logistics compared with combining separate agents.
| Property | Value | Notes |
|---|---|---|
| Molecular weight | Approximately 4,700 Da | Peptide of roughly forty amino acids |
| Receptor targets | GLP-1, GIP, glucagon | Triple agonist class |
| Research code | LY3437943 | Internal development designation |
| Compound class | Incretin mimetic peptide | Synthetic, not a biologic extract |
| Development status | Investigational | No general regulatory approval |
Development has progressed from single- and multiple-ascending-dose studies in healthy volunteers into larger randomized trials in adults with obesity, type 2 diabetes, and fatty liver disease. Early reports describe dose-dependent reductions in body weight and improvements in glycemic markers over treatment periods of several months. Whether the glucagon arm adds tolerability cost without added benefit is still debated. Long-term cardiovascular outcomes, effects after treatment stops, and performance in older or comorbid populations are open questions rather than settled findings. Approval status may change, so the current investigational label should be confirmed against regulatory sources.
Retatrutide is an investigational synthetic peptide developed under the code LY3437943, with a backbone derived from glucose-dependent insulinotropic polypeptide. Several non-proteinogenic residues, including alpha-aminoisobutyric acid, appear in that backbone, and a fatty diacid side chain attached through a linker extends circulation time. The molecule carries roughly thirty-nine amino acid units and a total mass near 4.7 kilodaltons. Administration is by subcutaneous injection once weekly. Published work uses both the name retatrutide and the code LY3437943.
Pharmacologically the compound activates three receptors: GLP-1, GIP, and glucagon. GLP-1 and GIP signaling contribute to glucose-dependent insulin release, delayed gastric emptying, and reduced appetite, while glucagon receptor activation is associated with increased energy expenditure and hepatic fat oxidation. The single-molecule design is intended to keep these activities in one peptide rather than combining separate agents. Relative activity at each receptor differs, and the balance between them is a central question in interpretation. The glucagon component is partly offset by incretin-mediated insulin secretion, an interaction that remains incompletely characterized.
稳定性研究一般关注脱酰胺、氧化与聚集三类降解路径。脱酰胺多发生在天冬酰胺残基上，氧化常涉及甲硫氨酸与色氨酸，聚集则与浓度、温度以及容器界面接触有关。强制降解实验用于识别分子中较敏感的位点。这些结果会直接影响储存条件的设定与有效期的判断。
冻干粉通常在低温环境下保存，复溶之后需要按指定条件在较短时间内使用。反复冻融和剧烈振荡可能促进聚集，低吸附容器则能减少多肽在管壁上的损失。批号、日期与处理条件的完整记录，是后续复核与问题追溯的基础。
Countries requiring passports valid for at least 4 months on arrival include Micronesia and Zambia. Countries requiring passports with a validity of at least 3 months beyond the date of intended departure include Azerbaijan, Bosnia and Herzegovina, Honduras, Montenegro, Nauru, Moldova and New Zealand. Similarly, the EEA countries of Iceland, Liechtenstein, Norway, all European Union countries (except Ireland) together with Switzerland also require 3 months validity beyond the date of the bearer's intended departure unless the bearer is an EEA or Swiss national. Countries requiring passports valid for at least 3 months on arrival include Albania, North Macedonia, Panama, and Senegal. Bermuda requires passports to be valid for at least 45 days upon entry. Countries that require a passport validity of at least one month beyond the date of intended departure include Eritrea, Hong Kong, Lebanon, Macau, the Maldives and South Africa.
=== Infants and microwave ovens === There are several cases of child abuse where an infant or child has been placed in a microwave oven. The typical feature of such injuries are well-defined burns on the skin nearest to the microwave emitter, and histology examination shows higher damage extent in tissues with high content of water (e.g., muscles) than in tissues with less water (e.g., adipose tissue). One such case involved a teenage babysitter who admitted to having placed a child in the microwave oven for approximately sixty seconds. The child developed a third degree burn to the back, measuring 5 inches x 6 inches. The babysitter later took the child to the emergency department, where multiple skin grafts were placed on the back. There were no signs of lasting emotional, cognitive or physical effects. CT scan of the head was normal, and there were no cataracts. Another case involved a five-week-old female infant that had multiple full-thickness burns totaling 11% of the body surface area. The mother claimed the infant had been near a microwave oven, but not inside it. The infant survived but required amputations of parts of one leg and one hand. Additionally, there have been two alleged infant deaths caused by microwave ovens. In all these cases, the babies were placed within microwaves and died of subsequent injuries.
=== Angular velocity === A MERU (milli Earth rate unit) is a measure of angular velocity equal to 1⁄1000 of Earth's rotation rate: 1 MERU = 7.292115×10^−8 radians per second or about 0.2625 milliradians/hour. It was introduced by MIT's Instrumentation Laboratories (now Draper Labs) to measure the performance of inertial navigation systems.
=== Comorbidity === Other psychological issues may factor into anorexia nervosa. Some pre-existing disorders can increase a person's likelihood to develop an eating disorder. Additionally, anorexia nervosa can contribute to the development of certain conditions. The presence of psychiatric comorbidity has been shown to affect the severity and type of anorexia nervosa symptoms in both adolescents and adults. Post-traumatic stress disorder remains highly prevalent among patients with anorexia nervosa, with more comorbid PTSD being associated with more severe eating disorder symptoms. Obsessive–compulsive disorder (OCD) and obsessive–compulsive personality disorder (OCPD) are highly comorbid with AN. OCD is linked with more severe symptomatology and worse prognosis. The causality between personality disorders and eating disorders has yet to be fully established. Other comorbid conditions include depression, alcoholism, substance abuse, borderline and other personality disorders, anxiety disorders, attention deficit hyperactivity disorder, and body dysmorphic disorder (BDD). Depression and anxiety are the most common comorbidities, and depression is associated with a worse outcome. Autism spectrum disorder occurs more commonly among people with eating disorders than in the general population, with about 30% of children and adults with AN likely having autism. Zucker et al. (2007) proposed that conditions on the autism spectrum make up the cognitive endophenotype underlying anorexia nervosa and appealed for increased interdisciplinary collaboration.
Sources: en.wikipedia.org
== External links == Histology image: 21301loa – Histology Learning System at Boston University - "Ultrastructure of the Cell: myelinated axon and Schwann cell" Histology image: 21401loa – Histology Learning System at Boston University - "Ultrastructure of the Cell: arteriole and peripheral nerve" Histology image: 1_03 at the University of Oklahoma Health Sciences Center Histology at University of California, Los Angeles Diagram at Howard University
==== Canada, United Kingdom, and Europe ==== In Canada, e-cigarettes had an estimated value of 140 million CAD in 2015. There are numerous e-cigarette retail shops in Canada. A 2014 audit of retailers in four Canadian cities found that 94% of grocery stores, convenience stores, and tobacconist shops which sold e-cigarettes sold nicotine-free varieties only, while all vape shops stocked at least one nicotine-containing product. By 2015, the e-cigarette market had only reached a twentieth of the size of the tobacco market in the UK. In the UK in 2015 the "most prominent brands of cigalikes" were owned by tobacco companies, however, with the exception of one model, all the tank types came from "non-tobacco industry companies". Yet some tobacco industry products, while using prefilled cartridges, resemble tank models. By 2023, 1 survey by the Local Data Company counted 3,573 specialist vape shops in the UK, and NIQ data cited in press reporting put value sales of vaping products in Britain at £897.4 million. Sky News similarly reported that more than 230 independent vape shops opened in 2023, citing the same Local Data Company survey. France's e-cigarette market was estimated by Groupe Xerfi to be €130 million in 2015. Additionally, France's e-liquid market was estimated at €265 million. In December 2015, there were 2,400 vape shops in France, 400 fewer than in March of the same year. Industry organization Fivape said the reduction was due to consolidation, not to reduced demand.
=== Cyclic peptides === Lin and her lab use computational chemistry to provide information on the solution structures of cyclic peptides. They recently successfully used molecular dynamics simulation with enhanced sampling methods to design well-structured cyclic peptides.
=== 1.3 === DisplayPort version 1.3 was approved on 15 September 2014. This standard increases overall transmission bandwidth to 32.4 Gbit/s with the new HBR3 mode featuring 8.1 Gbit/s per lane (up from 5.4 Gbit/s with HBR2 in version 1.2), for a total data throughput of 25.92 Gbit/s after factoring in 8b/10b encoding overhead. This bandwidth is enough for a 4K UHD display (3840 × 2160) at 120 Hz with 24 bit/px RGB color, a 5K display (5120 × 2880) at 60 Hz with 30 bit/px RGB color, or an 8K UHD display (7680 × 4320) at 30 Hz with 24 bit/px RGB color. Using Multi-Stream Transport (MST), a DisplayPort port can drive two 4K UHD (3840 × 2160) displays at 60 Hz, or up to four WQXGA (2560 × 1600) displays at 60 Hz with 24 bit/px RGB color. The new standard includes mandatory Dual-mode for DVI and HDMI adapters, implementing the HDMI 2.0 standard and HDCP 2.2 content protection. The Thunderbolt 3 connection standard was originally to include DisplayPort 1.3 capability, but the final release ended up with only version 1.2 for Intel 6000 Series Thunderbolt 3 Controllers. Later Intel 7000 Series Thunderbolt 3 controllers support DisplayPort 1.4 capability including HDR. The VESA's Adaptive Sync feature in DisplayPort version 1.3 remains an optional part of the specification.
The second approach utilizes diethyl carbonate in the presence of a strong base to give α-phenylcyanoacetic ester. Alkylation of this ester using ethyl bromide proceeds via a nitrile anion intermediate to give the α-phenyl-α-ethylcyanoacetic ester. This product is then further converted into the 4-iminoderivative upon condensation with urea. Finally acidic hydrolysis of the resulting product gives phenobarbital.
Sources: en.wikipedia.org
It is a synthetic peptide classified as a triple receptor agonist. It engages the GLP-1, GIP, and glucagon receptors at once. It is investigated for metabolic and weight-related conditions rather than approved for general use.
No regulatory agency has approved it for routine medical use. It remains an investigational compound studied in controlled trials. Access outside research settings is not established.
Each receptor influences energy balance through different pathways. Combining them is intended to add fat loss from lowered intake and higher expenditure. The optimal balance among the three effects is still under study.
It is described as a single molecule that acts at three receptors: the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This triple activity distinguishes it from agents that target one or two of these pathways.